There were 170 press releases posted in the last 24 hours and 191,080 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image